Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APG-157 |
| Synonyms | |
| Therapy Description |
APG-157 is a botanical drug comprising polyphenolic compounds, including curcumin, which potentially enhances antitumor immune response (PMID: 32022261). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APG-157 | APG 157|APG157 | APG-157 is a botanical drug comprising polyphenolic compounds, including curcumin, which potentially enhances antitumor immune response (PMID: 32022261). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05312710 | Phase II | APG-157 | Safety and Efficacy of APG-157 in Head and Neck Cancer | Unknown status | USA | 0 |
| NCT06011109 | Phase Ib/II | Bevacizumab APG-157 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Recruiting | USA | 0 |